Abstract
Accumulating evidence has suggested that cellular production of superoxide acts as an intracellular messenger to regulate gene expression and modulate cellular activities. In this report, we set out to investigate the role of active H-ras-mediated superoxide production on tumor cell malignancy in a SV-40 transformed human lung WI-38 VA-13 cell line. Stable transfection and expression of constitutively active mutant V12-H-ras (V12-H-ras) dramatically increased intracellular production of superoxide. The expression of V12-H-ras significantly enhanced cell proliferation, migration and resistance to TNF-α treatment compared to that of parental and vector control cells, while expression of wild type H-ras (WT-H-ras) only had modest effects. Upon scavenging by superoxide dismutase and other molecules that decrease the intracellular level of active H-ras mediated superoxide production, cell proliferation, migration and resistance to TNF-α were significantly reduced. Furthermore, we demonstrated that the activation of membrane NADPH oxidase activity by expression of active H-ras contributed to the intracellular superoxide production. The causal relationship between membrane superoxide production and increased cell proliferation, migration, and resistance to TNF-α by the expression of active H-ras, has provided direct evidence to demonstrate that superoxide acts as an intracellular messenger to cascade ras oncogenic signal relay and to modulate tumor malignant activity.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 50 print issues and online access
$259.00 per year
only $5.18 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Adler V, Yin Z, Tew KD, Ronai Z . 1999 Oncogene 18: 6104–6111
Ames BN, Shigenaga MK, Hagen TM . 1993 Proc. Natl. Acad. Sci. USA 90: 7915–7922
Atlante A, Calissano P, Bobba A, Azzariti A, Marra E, Passarella S . 2000 J. Biol. Chem. 275: 37159–37166
Bae YS, Sung J-Y, Kim O-S, Kim YJ, Hur KC, Kazlauskas A, Rhee SG . 2000 J. Biol. Chem. 275: 10527–10531
Bohler T, Waiser J, Hepburn H, Gaedeke J, Lehmann C, Hambach P, Budde K, Neumayer HH . 2000 Cytokine 12: 986–991
Brunet A, Pouyssenur J . 1996 Science 272: 1652–1655
Buettner GR . 1993 Arch. Biochem. Biophys. 300: 535–543
Cerutti PA . 1985 Science 227: 375–381
Clement M-V, Stamenkovi I . 1996 EMBO J. 15: 216–225
Crawford LE, Milliken EE, Irani K, Zweier JL, Becker LC, Johnson TM, Eissa NT . 1996 J. Biol. Chem. 271: 26863–26867
Dagher MC, Fuchs A, Bourmeyster N, Jouan A, Vignais PV . 1995 Biochimie 77: 651–660
Diekmann D, Abo A, Johnston C, Segal AW, Hall A . 1994 Science 265: 531–533
Emerit I, Cerutti PA . 1981 Nature 293: 144–146
Floyd RA . 1999 Proc. Soc. Exp. Biol. Med. 222: 236–245
Freeman JL, Abo A, Lambeth JD . 1996 J. Biol. Chem. 271: 19794–19801
Fridovich I . 1983 Ann. Rev. Pharma. Toxicol. 23: 239–257
Giri U, Iqbal M, Agarwal MK, Khan S, Athar M . 1999 Cancer Letter 135: 53–60
Hildeman DA, Mitchell T, Teague TK, Henson P, Day BJ, Kappler J, Marrack PC . 1999 Immunity 10: 735–744
Huang P, Feng L, Oldham EA, Keating MJ, Plunkett W . 2000 Nature 407: 390–395
Irani K, Xia Y, Zweier JL, Sollott SJ, Der CJ, Fearon ER, Sundaresan M, Finkel T, Goldschmidt-Clermont PJ . 1997 Science 275: 1649–1652
Irani K, Goldchmidt-Clermont PJ . 1998 Biochem. Pharma. 55: 1339–1346
Iwata K, Shibuya H, Ohkawa Y, Inui N . 1984 Toxicol. Letter 22: 75–81
Jaruga P, Zastawny TH, Skokowski J, Dizdroglu M, Olinski R . 1994 FEBS Lett. 341: 59–64
Jones SA, Wood JD, Coffey MJ, Jones OT . 1994 FEBS Lett. 355: 178–182
Jones SA, O'Donnell VB, Wood JD, Broughton JP, Hughes EJ, Jones OT . 1996 Am. J. Physiol. 271: H1626–H1634
Joneson T, McDonough M, Bar-Sagi D, Van Aelst L . 1996 Science 274: 1374–1376
Kamata H, Tanaka C, Yagisawa H, Matsuda S, Gotoh Y, Nishda E, Hirata H . 1996 J. Biol. Chem. 271: 33018–33025
Kennedy AR, Troll W, Little JB . 1984 Carcinogenesis 5: 1213–1218
Kheradmand F, Werner E, Tremble P, Symons M, Werb Z . 1998 Science 280: 898–902
Krieger-Brauer HI, Kather H . 1995a Biochem. J. 307: 543–548
Krieger-Brauer HI, Kather H . 1995b Biochem. J. 307: 549–556
Lee AC, Fenster BE, Ito H, Takeda K, Bae NS, Hirai T, Yu ZX, Ferrans VJ, Howard BH, Finkel T . 1999 J. Biol. Chem. 274: 7936–7940
Li N, Oberley TD, Oberley LW, Zhong W . 1998 Prostate 35: 221–233
Li S, Yan T, Yang JQ, Oberley TD, Oberley LW . 2000 Cancer Res. 60: 3927–3939
Liu R, Oberley TD, Oberley LW . 1997 Human Gene Therapy 8: 585–595
Liu R, Oberley TD, Oberley LW . 1998 Cell Growth Differ. 9: 239–246
Liu R, Narla RK, Kurinov I, Li B, Uckun FM . 1999 Rad. Res. 151: 133–141
Liu R, Buettner GR, Oberley LW . 2000 Free Rad. Biol. Med. 28: 1197–1205
Lo YYC, Cruz TF . 1995 J. Biol. Chem. 270: 11727–11730
Loschen G, Azzi A, Richter C, Flohe L . 1974 FEBS Letts. 42: 6874–6880
Meier B, Radeke HH, Selle S, Younes M, Sies H, Resch K, Habermehl GG . 1989 Biochem. J. 263: 539–545
Moldovan L, Moldovan NI, Sohn RH, Parikh SA, Goldschmidt-Clermont PJ . 2000 Circulation Res. 86: 549–557
Nakamura Y, Colburn NH, Gindhardt TD . 1985 Carcinogenesis 6: 229–235
Oberley LW, Buettner GR . 1979 Cancer Res. 39: 1141–1149
Ohba M, Shibannma M, Kuroki T, Nose KJ . 1994 J. Cell Biol. 126: 1079–1088
Pani G, Bedogni B, Anzevino R, Colavitti R, Palazzotti B, Borrello S, Galeotti T . 2000 Cancer Res. 60: 4654–4660
Pick E . 1986 Meth. Enzymol. 132: 407–421
Pretone WF, English DK, Wong K, McCord JM . 1980 Proc. Natl. Acad. Sci. USA 77: 1159–1165
Qiu R, Chen D, Kim D, McCormick F, Symons M . 1995 Nature 374: 457–460
Quinn M . 1995 J. Leukocyte Biol. 58: 263–276
Sofuni T, Ishidate Jr M . 1984 Mutation Res. 140: 27–31
Sundaresan M, Yu ZX, Ferrans VJ, Irani K, Fankel T . 1995 Science 270: 296–299
Thannickal VJ, Aldweib KDL, Fanburg BL . 1998 J. Biol. Chem. 273: 23611–23615
Ward RA, Nakamura M, McLeish KR . 2000 J. Biol. Chem. 275: 36713–36719
Yan T, Oberley LW, Zhong W, St. Clair DK . 1996 Cancer Res. 56: 2864–2871
Yang J-Q, Li S, Domann FE, Buettner GR, Oberley LW . 1999 Molec. Carcinogen. 26: 180–188
Zhai Q, Ji H, Zheng Z, Yu X, Sun L, Liu X . 2000 J. Cell. Physiol. 184: 161–170
Zhong W, Oberley LW, Oberley TD, St. Clair DK . 1997 Oncogene 14: 481–490
Zimmerman R, Cerutti PA . 1984 Proc. Natl. Acad. Sci. USA 81: 2085–2087
Acknowledgements
We thank Mr Geoff Modderman for his suggestion and technical assistance on the preparation of the manuscript.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Liu, R., Li, B. & Qiu, M. Elevated superoxide production by active H-ras enhances human lung WI-38VA-13 cell proliferation, migration and resistance to TNF-α. Oncogene 20, 1486–1496 (2001). https://doi.org/10.1038/sj.onc.1204214
Received:
Revised:
Accepted:
Issue Date:
DOI: https://doi.org/10.1038/sj.onc.1204214
Keywords
This article is cited by
-
Bach1 is critical for the transformation of mouse embryonic fibroblasts by RasV12 and maintains ERK signaling
Oncogene (2013)
-
Reactive oxygen species-mediated therapeutic control of bladder cancer
Nature Reviews Urology (2011)
-
Differential induction of reactive oxygen species through Erk1/2 and Nox-1 by FK228 for selective apoptosis of oncogenic H-Ras-expressing human urinary bladder cancer J82 cells
Journal of Cancer Research and Clinical Oncology (2011)
-
Role of reactive oxygen species in proapoptotic ability of oncogenic H-Ras to increase human bladder cancer cell susceptibility to histone deacetylase inhibitor for caspase induction
Journal of Cancer Research and Clinical Oncology (2009)
-
Pro-metastatic signaling by c-Met through RAC-1 and reactive oxygen species (ROS)
Oncogene (2006)